AX-2025-019922 · Ipamorelin · HJ lot HJ-2504-X6056

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.73	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.27	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — C-terminal free acid (+1 Da)	0.13	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	86.28	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	86.05	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	12.49	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	10.748	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	107.5	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	6.85	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	6.31	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.56	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White cake, partially collapsed	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.81	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	8.36	min	8.24 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.06	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	69,099	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.92	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 69,099, and skew follows the reported asymmetry factor of 1.06. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.13 % impurity against a 99.73 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Ipamorelin — main peak	8.36	4,847,187	99.73	—
2	C-terminal free acid (+1 Da)	8.54	6,318	0.13	+0.984
3	[D-Trp]-epimer	8.24	3,402	0.07	0.000
4	des-Lys (−128 Da)	8.14	1,944	0.04	-128.095
5	oxidised Trp (+16 Da)	8.02	1,458	0.03	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	6.85
Counter-ion (acetate)	ion chromatography	6.31
Residual solvent + inorganic residue	estimated	0.56
Total peptide content	by difference	86.28
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.69	99.73	divergence +0.09 pp vs batch median
Total impurities (% area)	0.31	0.27
Largest single impurity (% area)	0.12	0.13
Water (%)	4.9	6.85
Counter-ion (%)	not stated	6.31
Peptide content (%w/w)	not stated	86.28
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → third-party forwarder (13 d) → laboratory (courier, cold pack, 12 d) → assay.
Assay date: 01 Aug 2025
Submitted to the index: 10 Aug 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

sig_figs10 Aug 2025

Two decimal places on 99.73 % implies repeatability better than 0.01 pp, which no laboratory here claims. The number is sound; the printed precision is more than the method carries.

Index data team

Two decimal places are retained because the source reports carry them and truncating would discard information where a laboratory genuinely reports it. The uncertainty budget on /methods/uncertainty-budget/ is the right thing to read alongside any purity figure on this site.

prep_hplc_cut10 Aug 2025

0.27 % total impurities on Ipamorelin means the preparative fraction was cut narrow. That trades yield for purity, and the trade was made in the buyer's favour on this lot.

storage_stated10 Aug 2025

Purity 99.73 %, water 6.85 %, counter-ion 6.31 % acetate, mass balance closed, provenance independent. There is nothing outstanding on this record.

Section 7

Related records

Same batch — lot HJ-2504-X6056 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019915	HJ-2504-X6056	Nordanalyt	2025-Q3	99.58	6.69	91.4	Buyer-sourced	0	PASS
AX-2025-019916	HJ-2504-X6056	Janoshik	2025-Q3	99.82	7.43	—	Buyer-sourced	0	PASS
AX-2025-019917	HJ-2504-X6056	VendorInvestigate	2025-Q3	99.16	6.66	—	Buyer-sourced	0	PASS
AX-2025-019918	HJ-2504-X6056	Janoshik	2025-Q3	99.59	7.05	—	Buyer-sourced	0	PASS
AX-2025-019919	HJ-2504-X6056	Janoshik	2025-Q3	99.80	6.37	91.1	Buyer-sourced	0	PASS
AX-2025-019920	HJ-2504-X6056	Janoshik	2025-Q3	99.52	6.37	88.5	Buyer-sourced	1	MARGINAL
AX-2025-019921	HJ-2504-X6056	Medutest	2025-Q3	99.93	6.29	93.6	Buyer-sourced	1	FAIL
AX-2025-019923	HJ-2504-X6056	Janoshik	2025-Q3	99.60	6.80	91.8	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Ipamorelin records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041377	QYB	QYB-2605-H3558	Nordanalyt	2026-Q3	99.93	4.35	—	Buyer-sourced	0	PASS
AX-2026-041913	SinoPep	SNP-2606-L4478	PeptideMeter	2026-Q3	98.88	5.28	—	Buyer-sourced	0	FAIL
AX-2026-041914	SinoPep	SNP-2606-L4478	Janoshik	2026-Q3	99.14	5.49	—	Buyer-sourced	0	PASS
AX-2026-041909	SinoPep	SNP-2606-L4478	PeptideMeter	2026-Q3	99.00	5.48	89.5	Buyer-sourced	1	MARGINAL
AX-2026-041895	SinoPep	SNP-2602-B3833	Janoshik	2026-Q3	99.93	4.72	105.9	Buyer-sourced	1	MARGINAL
AX-2026-041898	SinoPep	SNP-2602-B3833	Nordanalyt	2026-Q3	99.93	4.54	96.0	Buyer-sourced	1	MARGINAL
AX-2026-041899	SinoPep	SNP-2602-B3833	PeptideMeter	2026-Q3	99.93	4.96	90.1	Buyer-sourced	1	MARGINAL
AX-2026-041891	SinoPep	SNP-2602-B3833	Janoshik	2026-Q3	99.93	5.11	—	Buyer-sourced	1	MARGINAL

Other recent HJ records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042595	Semaglutide	HJ-2608-C7002	Janoshik	2026-Q3	99.50	3.55	—	Buyer-sourced	1	MARGINAL
AX-2026-042598	Semaglutide	HJ-2608-C7002	Janoshik	2026-Q3	99.59	3.84	—	Buyer-sourced	0	PASS
AX-2026-042605	Semaglutide	HJ-2608-C7002	Janoshik	2026-Q3	99.03	3.37	107.3	Buyer-sourced	0	PASS
AX-2026-042602	Semaglutide	HJ-2608-C7002	Nordanalyt	2026-Q3	99.21	3.50	92.0	Buyer-sourced	0	PASS
AX-2026-042603	Semaglutide	HJ-2608-C7002	Janoshik	2026-Q3	99.16	3.42	105.9	Buyer-sourced	0	PASS
AX-2026-042528	GHRP-6	HJ-2603-R5329	VendorInvestigate	2026-Q3	98.69	1.87	95.8	Buyer-sourced	0	FAIL
AX-2026-042526	GHRP-6	HJ-2603-R5329	Medutest	2026-Q3	99.37	3.06	—	Laboratory-retained	0	PASS
AX-2026-042527	GHRP-6	HJ-2603-R5329	VendorInvestigate	2026-Q3	99.21	2.77	93.2	Buyer-sourced	0	PASS